Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

Cimerli Offers a New, Interchangeable Biosimilar for Ocular Conditions

May 15th 2025

By Melissa Garcia, PharmD Candidate

Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective vascular endothelial growth factor inhibition.

Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA

May 13th 2025

By Skylar Jeremias

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.

Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics

May 13th 2025

By Skylar Jeremias

Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its health system—but a new report suggests biosimilars could offer financial relief, provided uptake barriers are addressed through policy reform and education.

Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs

May 10th 2025

By Deana Ferreri, PhD

Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.

Eye on Pharma: Interchangeability, Private Labels, and Patent Settlements for Biosimilars

May 9th 2025

By Skylar Jeremias

The Top 5 Biosimilar Articles for the Week of May 5

May 9th 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of May 5, 2025.

Targeted Reimbursement Encourages Oncology Biosimilar Use

May 7th 2025

By Skylar Jeremias

Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.

Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow

May 6th 2025

By Cameron Santoro

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.

BioRationality: A New Bill to Transform the Future of Biosimilars

May 5th 2025

By Sarfaraz K. Niazi, PhD

Escaping the Void: All Things Biosimilars With Craig & G

May 4th 2025

By Craig Burton

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."